Literature DB >> 10868358

Functional results at the end of skeletal growth in 30 patients affected by congenital pseudoarthrosis of the tibia.

C Tudisco1, G Bollini, P Dungl, J Fixen, F Grill, F Hefti, B Romanus, S Wientroub.   

Abstract

From a multicentric study on Congenital Pseudoarthrosis of the tibia (CPT) conducted on 340 patients, we evaluated the functional results on a group of thirty patients who were at the end of skeletal growth (age < or = 16 years). The prognosis of CPT is very much related to the radiologic classification. Crawford type 2 and Crawford type 4 pseudoarthrosis have a worse prognosis, with a lower percentage of fusion at the site of pseudoarthrosis. Crawford 4 patients have the worst functional results. Most of them showed a severe leg length discrepancy, needed a permanent brace, with an ankle joint function fair or poor. The presence of fibula pseudoarthrosis seems to be responsible for most of the worst functional results. The level of deformity caused by either the natural course of the disease or its treatment, is decisive in the evaluation of the functional results.

Entities:  

Mesh:

Year:  2000        PMID: 10868358     DOI: 10.1097/01202412-200004000-00004

Source DB:  PubMed          Journal:  J Pediatr Orthop B        ISSN: 1060-152X            Impact factor:   1.041


  13 in total

1.  Isolated congenital pseudarthrosis of the fibula: A report of two cases and review of the literature.

Authors:  T Cherrad; H Zejjari; H Bousbaä; J Louaste; K Rachid; L Amhajji
Journal:  J Clin Orthop Trauma       Date:  2018-07-05

Review 2.  Ilizarov treatment of congenital pseudarthrosis of the tibia: a multi-targeted approach using the Ilizarov technique.

Authors:  In Ho Choi; Tae-Joon Cho; Hyuk Ju Moon
Journal:  Clin Orthop Surg       Date:  2011-02-15

3.  Relationship between postoperative complications and fibular integrity in congenital pseudarthrosis of the tibia in children.

Authors:  Yao-Xi Liu; Hai-Bo Mei; Guang-Hui Zhu; Rong-Guo He; Kun Liu; Jin Tang; Jiang-Yan Wu; Wei-Hua Ye; Xin Hu; Qian Tan; An Yan; Sheng-Xiang Huang; Xiao-Qian Tan; Ting Lei
Journal:  World J Pediatr       Date:  2016-12-23       Impact factor: 2.764

4.  Successful treatment of congenital pseudarthrosis of the tibia: still a challenge.

Authors:  K Bobotas; S N Lallos; V S Nikolaou; D S Kοrres; N E Efstathopoulos
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-09-02

5.  Functional and radiological outcomes after treatment of congenital pseudarthrosis of the tibia using the Ilizarov technique: a retrospective single-center study.

Authors:  Ahmed Ibrahim Zayda; Mohamed Kamal Mesregah; Soliman Hassan Zalalo; Samy Abdel-Hady Sakr
Journal:  J Orthop Traumatol       Date:  2022-09-23

6.  Combination of the Ilizarov Method and Intramedullary Fixation for the Treatment of Congenital Pseudarthrosis of the Tibia in Children: A Retrospective Observational Study.

Authors:  Ainizier Yalikun; Maimaiaili Yushan; Yimurang Hamiti; Cheng Lu; Aihemaitijiang Yusufu
Journal:  Front Surg       Date:  2022-05-17

7.  Congenital pseudarthrosis of the tibia: the results of an evolving protocol of management.

Authors:  N Nicolaou; A Ghassemi; R A Hill
Journal:  J Child Orthop       Date:  2013-06-12       Impact factor: 1.548

8.  Health-related quality of life measures in genetic disorders: an outcome variable for consideration in clinical trials.

Authors:  David A Stevenson; John C Carey
Journal:  Am J Med Genet C Semin Med Genet       Date:  2009-08-15       Impact factor: 3.908

9.  Analysis of radiographic characteristics of anterolateral bowing of the leg before fracture in neurofibromatosis type 1.

Authors:  David A Stevenson; John C Carey; David H Viskochil; Laurie J Moyer-Mileur; Hillarie Slater; Mary A Murray; Jacques L D'Astous; Kathleen A Murray
Journal:  J Pediatr Orthop       Date:  2009-06       Impact factor: 2.324

10.  Congenital pseudarthrosis of the tibia: Management and complications.

Authors:  Hitesh Shah; Marie Rousset; Federico Canavese
Journal:  Indian J Orthop       Date:  2012-11       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.